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A  substantial  body  of evidence  implicates  prostaglandins  (PG)  as  potent  local 
regulators of the immune response (1, 2). Inhibition of human T  cell proliferation by 
PG  of  the  E  type  (PGE)  is  well  established  (3),  but  the  mechanism  is  poorly 
understood. The discovery of interleukin 2 (IL-2), the lymphokine required for T  cell 
proliferation (4, 5), has permitted further elucidation of this inhibitory event. Previ- 
ously, it was shown  (6,  7) that exogenous PGE inhibited  lymphokine production by 
guinea  pig  lymph  node  lymphocytes, and  recently  it  was  reported  (8)  that  PGE 
suppressed IL-2 production by murine lymphocytes. We report here that PGE inhibits 
the production of IL-2 by normal human peripheral blood lymphocytes, whereas PG 
of the  type  F  (PGF)  or A  (PGA)  do  not.  Further,  we  found  that  PG  synthetase 
inhibitors  raised  IL-2  above  normal  levels.  Removal  of glass-adherent  cells  from 
mononuclear cell populations also led to increased IL-2 production by nonadherent 
cells. These cells were less responsive to stimulation by PG synthetase inhibitors but 
remained sensitive to inhibition by PGE. The results indicate that PGE, secreted by 
an adherent cell population, regulates the production of IL-2. 
Materials and Methods 
Separation of Lymphocytes.  Peripheral  venous blood, drawn  from normal fasting men and 
women into  heparinized Vacutainer tubes  (Beeton  Dickinson & Co.,  Rutherford,  N  J)  was 
centrifuged at 1,200 g for 4 rain to reduce volume and achieve partial separation of cells. After 
removal of plasma, the white cell layer was recovered and diluted with an equal volume of 
Hanks' balanced  salt  solution  (HBSS).  Mononuclear  cells  were  isolated  by  Ficoll-Paque 
(Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N  J) density gradient centrif- 
ugation. The resultant lymphocyte-rich bands (unfractionated lymphocytes) were washed three 
times in HBSS and suspended in Hepes-huffered RPMI  1640 medium (M. A. Bioproducts, 
Walkersville,  MD) containing 100 #g/ml streptomycin, 100 U/ml penicillin,  2.5 #g/ml Fungi- 
zone,  and 5  ×  10  -n M  2-mercaptoethanol (complete medium).  Cell  viability was >90%  as 
determined by the trypan blue exclusion  method. In some experiments, the blood was first 
passed through two successive glass wool columns (Pyrex wool; Coming Glass Works, Coming, 
NY) (600 g/10-cc syringe)  to remove adherent cells. This adherent cell-depleted suspension  is 
referred to as the nonadherent mononuclear cell population. 
Production of IL-2.  Unfractionated or nonadherent mononuclear cells were cultivated at a 
concentration of 10  e cells/ml in complete medium supplemented with  2% heat-inactivated 
human AB serum. Cultures containing  1 #g/ml phytohemagglutinin (PHA)  (Wellcome Re- 
agents, Ltd.,  Beekenharn,  England)  were incubated in the presence and absence of various 
compounds (PG, indomethacin or fentiazac)  for 48 h at 37°C in a humidified atmosphere of 
5% COs. After incubation, culture supernatants (conditioned medium [CM]) were sterilized by 
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passage through 0.45-#m Acrodisc filters  (Gelman Sciences, Inc., Ann Arbor, MI) and stored 
frozen at or below -20°C until assayed. 
Prostaglandins  El,  E2,  F1a, Fz,,  A1,  and  Az  (Sigma Chemical Co.,  St.  Louis,  MO)  were 
dissolved  in  absolute ethanol and diluted  in complete medium. The final concentration of 
ethanol  in  the cultures was --<0.1%. Controls established that  this  level of ethanol  did  not 
interfere with the production or assay of IL-2. Indomethacin (Merck Sharp and Dohme, West 
Point, PA) and fentiazac (Wy-21,894; Wyeth Laboratories, Philadelphia, PA) were dissolved in 
phosphate-buffered saline, pH 7.2, and diluted in complete medium. 
Measurement of IL-2.  IL-2  levels  were  determined  by  measuring  the  ability  of CM  to 
stimulate proliferation of sensitized normal human lymphocytes. The assay cells (0.3 ×  10  e per 
ml) were cultured in complete medium with 20% heat-inactivated fetal calf serum (A-FCS) 
(Gibco, Grand Island, NY) and 1 #g/ml PHA for 7 d at 37 ° in a humidified atmosphere of 5% 
CO2. Before assay, the cells were washed three times with HBSS, counted, and suspended (106 
cells per ml)  in complete medium containing 40% A-FCS. Aliquots of 105 cells (100 #1) were 
distributed in the wells of Linbro microtiter plates (Flow Laboratories, Inc., Hamden, CT), and 
test samples (100 #1 per well) were added in quadruplicate. The plates were incubated tor 48 
h at 37 °  in a  humidified atmosphere of 5% CO2. The cultures were then incubated with  1 
#Ci/well of [SH]thymidine  (New England Nuclear, Boston, MA), and 16-18 h later they were 
harvested on glass fiber filters using a Titertek cell harvester (Flow Labortories, Inc., McLean, 
VA).  The incorporated radioactivity retained by the  filters  was determined  using a  liquid 
scintillation  counter. Data were evaluated using the following equation: 
t 
cp__m tes_t sample  1) ×  100, 
cpm control 
where the control sample represents CM produced by PHA alone, and the test sample represents 
CM produced by PHA and PG or drug. To rule out proliferation because of PHA present in 
the samples,  assay cells were routinely tested for their response  to fresh PHA (1 /~g/ml) and 
found to be consistently unresponsive. 
Results and Discussion 
Using human mononuclear cells isolated by Ficoll-Paque gradient centrifugation, 
we investigated the effect of several PG on the production of IL-2. CM were prepared 
from  PHA-stimulated  lymphocyte cultures  incubated  for 48  h  in  the  presence  or 
absence  of PGEI,  PGE~,  PGFI~,  PGF~,  PGA1,  and  PGA~.  Data  from  these  and 
subsequent experiments were evaluated by analysis of variance (9). When tested over 
a dose range of 0.01-10 #g/ml, PGEI and PGE2 inhibited IL-2 production in a dose- 
dependent  manner,  and  they  were  inhibitory  at  physiological  concentrations  (10 
ng/ml)  (Fig.  1).  In contrast,  PGFI~, PGFz,,  PGA1, and  PGA2  (not  shown)  did  not 
significantly  inhibit  IL-2  production,  except  that  in  this  case,  PGF2~  and  PGAI 
inhibited  at  high  concentrations  (Fig.  1).  Inhibition  by PGFI~ and  PGAI at  these 
levels was not  consistently observed, whereas  in  10 out  of 12  donors,  PGE~, at  0.1 
/xg/ml, inhibited IL-2 production by >50% (P <  0.01). 
Because PG of the E  type specifically inhibited  IL-2, we cultivated mononuclear 
cells in the presence of two PG synthetase inhibitors, indomethacin (10) and fentiazac 
(11).  When  PHA-induced  lymphocyte cultures  were  incubated  in  the  presence  of 
optimum concentrations of either inhibitor (1-5 #g/ml for indomethacin;  1-10/~g/ml 
for  fentiazac),  IL-2  levels  increased  100-500%  (Fig.  2).  Thus,  treatment  with  PG 
synthetase inhibitors  augmented production of IL-2. Inouye et al.  (12)  also demon- 
strated  that  indomethacin  enhanced  IL-2 production  by human  mononuclear cells 
(as did removal of adherent cells)  in a  study evaluating methods for increasing the 
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FIo.  1.  Effect  of various prostaglandins  (PG)  on  PHA-induced production  of interleukin  2  by 
lymphocytes from  a  representative  normal  human  donor.  IL-2  levels  of CM,  prepared  in  the 
presence of PHA and  varying concentrations of different  PG,  were  determined  as  described  in 
Materials and Methods. The response of assay cells to PHA (1 #g/ml), complete medium, and to 
48-h supernatant from resting lymphocyte cultures was 4,329  ±  124 cpm,  1,698:1:51  cpm, and 
1,330  ±  46  cpm,  respectively. The response of assay cells to  the various  PG was similar to  the 
response to medium or to supernatant from resting lymphocyte cultures. 
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FIG.  2.  Effect of the PG synthetase inhibitors, ]ndomethacin and fentiazac, on the production of 
interleukin  2  by  unfractionated  mononuclear  cells.  CM  obtained  from  cells  cultivated  in  the 
presence of PHA (1/tg/ml) and varying concentrations of indomethacin or fentiazac were assayed 
as described  in  Materials  and Methods. The results from three separate donors are  reported  as 
percent enhancement relative to interleukin 2 production in the presence of PHA alone. Significant 
enhancement (P <  0.05)  was observed for all  drug concentrations at  or above 0.04 #g/ml. The 
response of assay cells to PHA-induced CM was 14,092 +  541 cpm for donor I; 44,373 -1- 1,084 cpm 
for donor J;  and 32,691  ±  1,082  cpm for donor K. The responses of assay cells to (a)  medium; (b) 
medium containing fresh PHA (1 /~g/ml); and  (c)  48-h culture supernatant from corresponding 
resting lymphocyte cultures were:  (a)  1,085  +  14 cpm,  (b)  1,617  +  91  cpm, and (c)  1,920 ±  130 
cpm for donor I;  (a)  3,783 ±  68 cpm, (b) 8,166 ±  271 cpm, and (c) 4,235 ±  140 epm for donor J; 
and  (a)  661  ±  72 cpm,  (b)  957  ±  47 cpm, and  (c)  1,147  ±  29 cpm for donor K.  Fentiazac, O; 
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TABLE  I 
Effect of the Removal of Adherent  Cells fiom Mononuclear Cell Populations on 
the Production of Interleukin  2 
Interleukin 2-mediated lymphocyte transformation 
[aH]thymidine incorporation* 
Donor 
Unffactionated mononuclear  Nonadherent mononuclcar 
cells:~  cells§ 
cpm ± SE 
A  34,062 -t- 1,159  87,711 4- 2,433 
B  54,870 4- 4,497  78,880 4- 3,475 
C  14,092 4- 541  135,336 4- 2,825 
D  8,080 4- 164  61,187 4- 2,667 
E  6,367 4- 426  66,587 4- 3,433 
F  6,781 4- 418  166,093 4- 7,084 
G  3,344 4- 234  88,400 4- 2,759 
H  30,085 4- 865  155,308 4- 2,390 
*  18-20 h  before  harvest  the  cells  were  labeled  with  1 #Ci/mi  [aH]thymidine (>15 
Ci/mmol). The results represent the mean of quadruplicate determinations for each 
condition. The mean response of assay cells to medium and to medium containing fresh 
PHA  (1  ~tg/ml)  was  1,556 4-  356 clam and 3,646 4-  949 cpm, respectively, over all 
experiments. The  reapons¢ of assay cells to conditioned medium from donor-paired 
unfractionated and nonadherent cell populations was found to be significantly  different 
by two-way analysis of variance (P <  0.001) for all donors. 
:~ The mean response of assay cells to supernatants from resting unfractionated lympho- 
cytes was 1,864 4- 244 cpm (n =  8). 
§ The mean response of assay cells to superuatants from resting nonadherent lymphocyteS 
was 1,797 +  348 cpm (n =  8). 
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Fro.  3.  Effect of indomethacin and PGE2 on production of IL-2 by unfractionated and nonadher- 
ent mononuclear cell populations.  PHA-stimulated cultures of unfractionated  and  nonadherent 
cells, corresponding to those described in Table I, were incubated with indomethacin (1/tg/ml) or 
PGEa (1/tg/ml) for 48 h at 37°C in a humidified atmosphere of 5% CCh. CM were prepared and 
assayed as described in Materials and Methods. The results are given as percent enhancement (for 
indomethacin) or percent inhibition (for PGEz) relative to IL-2 production in the presence of PHA 
alone.  Statistical evaluation of the data  by two-way analysis  of variance showed a  significant 
difference in the response of unfractionated and nonadherent cells to indomethacin (P< 0.003) but 
showed no significant difference in the response of both cell populations to PGEz (P >  0.5). 
Goodwin  et  al.  (13)  identified  a  population  of human  glass-adherent  cells  that 
produce  PGE2  and  suppress  T  cell  mitogenesis.  We  studied  IL-2  production  after 
removing such  cells.  A  comparison  of IL-2 production  by nonadherent  and  unfrac- 
tionated  mononuclear  cell populations  from several donors  revealed that  removal of RAPD~PORT AND DODGE  BRIEF  DEFINITIVE REPORT  947 
adherent cells significantly promoted IL-2 production  (Table I). It is possible that 
donor to donor variation in IL-2 production, observed before removal of adherent 
cells  (Table  I),  may be  due  in  part  to  variation  in  endogenous  PGFa  levels.  In 
addition, nonadherent cells were far less sensitive to stimulation by indomethacin (or 
fentiazac),  but  they were  equally sensitive  to  inhibition  by  PGFa  (Fig.  3).  This 
observation suggests that PG synthetase inhibitors act preferentially on adherent cells. 
The increase in production of IL-2 by nonadberent cells is probably not the result of 
an increased density of these cells in nonadherent vs. unfractionated cell populations 
because the number of monocytes initially present in peripheral blood is only 4% (14). 
Nor could the enhancement in IL-2 production be attributed to effects of indometh- 
acin, fentiazac, or PHA on the assay cells, because these compounds did not signifi- 
cantly stimulate [aH]thymidine incorporation. Rather, the data indicate that removal 
of a PG-producing adherent cell enhances IL-2 production by eliminating the major 
source  of PGE~.  This  would  explain  the  observation  that  adherent  cell-depleted 
cultures were less responsive to indomethancin than were unfractionated cultures. 
Recently, several other investigators (15-19)  have demonstrated a requirement for 
the macrophage product, interleukin 1 (IL-1), in the production of IL-2 by murine 
lymphocytes. Moreover, Maizel et al. (20) reported that human monocyte-produced 
IL-1 augments lectin-stimulated mitogenesis of human T cells purified from peripheral 
blood. In contrast, we found that in vitro production of IL-2 by peripheral human 
lymphocytes is not dependent on an adherent cell being present. Indeed, removal of 
adherent  cells resulted  in  enhanced  IL-2  production.  The  difference between  the 
findings may stem from the use by Maizel et al. of dialyzed macrophage-derived CM 
and/or purified IL-1 to demonstrate stimulation ofT cell proliferation: such materials 
would be depleted of PGE produced by adherent cells.  Although our results do not 
contradict  the  evidence  of a  T  cell  requirement  for  IL-1,  they  do  suggest  that 
peripheral blood lymphocytes do not require de novo synthesis of IL-1 for the produc- 
tion, secretion, and utilization of IL-2 in vitro. 
The present findings support the concept that PGE2, produced by an adherent cell 
population, plays a major role in the down-regulation of IL-2. Moreover, the fact that 
this mechanism acts across species lines underscores the relevance of animal models in 
the development of new drug therapies for modulation of PGE and T cell proliferative 
responses in human disease. 
Summary 
Prostaglandins of the E type specifically inhibited the production of interleukin 2 
(IL-2)  by normal  human  lymphocytes, whereas  PG  synthetase inhibitors  such  as 
indomethacin and fentiazac raised IL-2 production above normal levels. Removal of 
adherent  cells  from mononuclear cell  populations  also  resulted  in  enhanced IL-2 
production. The resultant nonadherent cell population lost sensitivity to the enhance- 
ment effect of PG synthetase inhibitors, suggesting that a  PGE-producing adherent 
cell plays a major role in the regulation of IL-2. 
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